Sidhaant Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sidhaant Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $3.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sidhaant Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $3.0M Trade | TransData Nexus

Sidhaant Life Sciences Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $3.0M Total Trade · DGFT Verified

Sidhaant Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.0M across 4 products in 4 therapeutic categories. Based on 63 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Folic ($1.0M), Quinine ($850.0K), Erythromycin ($750.0K).

Sidhaant Life Sciences Private Limited — Export Portfolio & Destination Treemap

Sidhaant Life Sciences Private Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sidhaant Life Sciences Private Limited? — Company Overview & Market Position

Sidhaant Life Sciences Private Limited, incorporated on October 1, 2004, is a private limited company based in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51397DL2004PTC129632. Its authorized capital stands at ₹10 million, with a paid-up capital of ₹7.65 million. The registered office is located at 808 8th Floor, Vishal Tower, District Centre, Janakpuri, New Delhi, 110058.

Sidhaant Life Sciences specializes in the wholesale and retail trade of pharmaceutical products, including tablets, capsules, syrups, and injections. The company has a workforce of approximately 12 employees as of April 8, 2024. Financially, the company reported a 24.8% decrease in total revenue for the fiscal year 2023, with a net profit decline of 69.49%.

What Does Sidhaant Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Folic$1.0M 2Quinine

Product Portfolio — Top 4 by Export Value

Sidhaant Life Sciences Private Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Folic	Nutritional Supplements	$1.0M	23	1.9%	11
2	Quinine	Antimalarial & Antiparasitic	$850.0K	17	4.4%	2
3	Erythromycin	Antibiotics	$750.0K	15	0.9%	12
4	Enoxaparin	Cardiovascular	$400.0K	8	0.2%	12

Sidhaant Life Sciences Private Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $3.0M. The top category is Nutritional Supplements (34.3% of portfolio), followed by Antimalarial & Antiparasitic (27.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sidhaant Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sidhaant Life Sciences operates manufacturing facilities in New Delhi and Gurugram, Haryana. The New Delhi facility is situated at 808 8th Floor, Vishal Tower, District Centre, Janakuri, New Delhi, 110058. The Gurugram facility is located at Basement, Ground, and First Floor, Plot-459, Phase III, Udyog Vihar, Gurugram, Haryana, 122008. Specific details regarding production capacities and specializations are not publicly disclosed.

3Key Leadership

The board of directors at Sidhaant Life Sciences comprises:

Sudarshan Sabharwal
Jetender Sabharwal
Sulabh Nayar
Anu Nayar
Sidhaant Sabharwal

These individuals have been associated with the company since its inception on October 1, 2004. Detailed information regarding their specific roles and professional backgrounds is not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sidhaant Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sidhaant Life Sciences has engaged in exporting pharmaceutical formulations to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals from the Directorate General of Foreign Trade (DGFT) for these exports. However, specific details regarding approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), and Pharmaceuticals and Medical Devices Agency (PMDA) are not publicly disclosed.

2Emerging Markets

Sidhaant Life Sciences has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's export activities in these regions are facilitated by obtaining export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT). Specific details regarding WHO prequalification or other certifications enabling market access are not publicly available.

3Geographic Strategy

Sidhaant Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Sidhaant Life Sciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company has engaged in exporting pharmaceutical formulations to the United States; however, detailed regulatory approval statuses are not disclosed.

2WHO & EU GMP

Sidhaant Life Sciences has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications are essential for exporting pharmaceutical products to international markets. Specific details regarding the scope and validity of these certifications are not publicly disclosed.

3CDSCO & Indian Regulatory

The company holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained state drug controller approvals for its facilities. Additionally, Sidhaant Life Sciences has secured export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities. Specific details regarding the validity and scope of these approvals are not publicly available.

Sidhaant Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sidhaant Life Sciences operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly disclosed, the company's diversified product portfolio and international presence position it as a notable competitor in the industry. The company's focus on quality manufacturing and adherence to international standards enhances its competitive edge.

2Key Differentiators

Sidhaant Life Sciences' key differentiators include its diversified product portfolio across multiple therapeutic categories, adherence to international quality standards, and a strategic focus on expanding its international market presence. These factors contribute to the company's ability to meet diverse customer needs and maintain a competitive position in the global pharmaceutical export market.

3Strategic Position

Sidhaant Life Sciences is strategically positioned as a pharmaceutical exporter with a focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's future outlook involves expanding its international footprint, enhancing product offerings, and maintaining compliance with global regulatory standards to meet the evolving demands of the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Sidhaant Life Sciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sidhaant Life Sciences has a track record of consistent export activities, with a total export value of $3.0 million USD across 63 shipments from 2022 to 2026. The company's portfolio includes four products across four therapeutic categories, with the top five products contributing to 100% of the export value. This indicates a focused approach to its export strategy, emphasizing quality and specialization.

2Certifications to Verify

Importers should verify the following certifications when considering products from Sidhaant Life Sciences:

FDA Approval: Confirm the FDA registration status of the manufacturing facility and the approval of specific products.

WHO-GMP Certification: Ensure the manufacturing facility holds valid WHO-GMP certification, indicating compliance with international quality standards.

EU GMP Certification: Verify the validity of EU GMP certification for the manufacturing facility, ensuring adherence to European Union quality standards.

Frequently Asked Questions — Sidhaant Life Sciences Private Limited

How many pharmaceutical products does Sidhaant Life Sciences Private Limited export from India?

Sidhaant Life Sciences Private Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Folic ($1.0M), Quinine ($850.0K), Erythromycin ($750.0K), Enoxaparin ($400.0K). Total export value is $3.0M.

What is Sidhaant Life Sciences Private Limited's total pharmaceutical export value?

Sidhaant Life Sciences Private Limited's total pharmaceutical export value is $3.0M, based on 63 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sidhaant Life Sciences Private Limited cover?

Sidhaant Life Sciences Private Limited exports across 4 therapeutic categories. The largest are Nutritional Supplements (34.3%, 1 products), Antimalarial & Antiparasitic (27.9%, 1 products), Antibiotics (24.6%, 1 products).

Get Full Sidhaant Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.